Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Mabwell (Shanghai) Bioscience Co. Ltd. manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. The busiest examiner for the company is WITHERSPOON, SIKARL A, who is responsible for 1 pending office action. This distribution means that each of the 2 pending actions is being reviewed by a different examiner in a different art unit.
Because there is no overlap between the 2 examiners or the 2 art units, the company cannot rely on a single unified strategy for its current pending matters. Each case must be handled according to the specific tendencies of the individual examiner and the standards of the respective art unit within the Biotechnology & Pharmaceuticals field. This fragmentation suggests that the 2 pending actions may cover diverse technical aspects of the company's technology. Practitioners should monitor the feedback from both examiners to identify any potential conflicts in claim scope or interpretation across the portfolio. The outcome of these 2 pending office actions will provide a baseline for future filings in these specific art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WITHERSPOON, SIKARL A | 1 | 86.3% | -20.1% |
| DONOGHUE, BRITTNEY ERIN | 1 | 59.0% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682062 | METHOD FOR SYNTHESIZING 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED THEREIN | WITHERSPOON, SIKARL A | — |
| 18557917 | ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF | DONOGHUE, BRITTNEY ERIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557917 | ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF | DONOGHUE, BRITTNEY ERIN | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682062 | METHOD FOR SYNTHESIZING 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED THEREIN | WITHERSPOON, SIKARL A | 1692 | §101§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18557917 | ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §102§103§112Other | Non-Final OA | — | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMabwell (Shanghai) Bioscience Co. Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Sikarl A Witherspoon has the most, with 1 of Mabwell (Shanghai) Bioscience Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.